Cardiovascular disease models: A game changing paradigm in drug discovery and screening. (April 2019)

• Record Type: Journal Article
• Authors: Savoji, Houman; Mohammadi, Mohammad Hossein; Rafatian, Naimeh; Toroghi, Masood Khaksar; Wang, Erika Yan; Zhao, Yimu; Korolj, Anastasia; Ahadian, Samad; Radisic, Milica
• Is Part Of: Biomaterials. Volume 198(2019)
• Page Start: 3
• Page End: 26
• Publication Date: 2019-04
• Subjects: Cardiovascular diseases -- In vitro disease models -- In silico disease models -- In vivo disease models -- Drug discovery -- Human induced pluripotent stem cells -- Organ-on-a-chip -- Cardiomyocyte; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2018.09.036
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Cardiovascular disease is the leading cause of death worldwide. Although investment in drug discovery and development has been sky-rocketing, the number of approved drugs has been declining. Cardiovascular toxicity due to therapeutic drug use claims the highest incidence and severity of adverse drug reactions in late-stage clinical development. Therefore, to address this issue, new, additional, replacement and combinatorial approaches are needed to fill the gap in effective drug discovery and screening. The motivation for developing accurate, predictive models is twofold: first, to study and discover new treatments for cardiac pathologies which are leading in worldwide morbidity and mortality rates; and second, to screen for adverse drug reactions on the heart, a primary risk in drug development. In addition to in vivo animal models, in vitro and in silico models have been recently proposed to mimic the physiological conditions of heart and vasculature. Here, we describe current in vitro, in vivo, and in silico platforms for modelling healthy and pathological cardiac tissues and their advantages and disadvantages for drug screening and discovery applications. We review the pathophysiology and the underlying pathways of different cardiac diseases, as well as the new tools being developed to facilitate their study. We finally suggest a roadmap for employing these non-animal platforms in assessing drug cardiotoxicity and safety.